Advances in Long Non-coding RNAs on Resistant to EGFR-TKIs
in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2018.02.06
- Author:
Shubin LI
1
;
Hong YU
2
;
Gengyue ZHANG
2
Author Information
1. Department of Internal Medicine, Southern Branch of Guang'anmen Hospital, China Academy of Chinese Medical Sciences,
Beijing 102600, China.
2. Cell Biology Laboratory, Jilin Province Institute of Cancer Prevention and Treatment, Jilin Cancer Hospital, Changchun 130012, China.
- Publication Type:Journal Article
- Keywords:
Epidermal growth factor receptor-tyrosine kinase inhibitors;
Long non-coding RNA;
Lung neoplasms;
Resistance
- MeSH:
Carcinoma, Non-Small-Cell Lung;
drug therapy;
genetics;
Drug Resistance, Neoplasm;
genetics;
ErbB Receptors;
antagonists & inhibitors;
Humans;
Lung Neoplasms;
drug therapy;
genetics;
Protein Kinase Inhibitors;
pharmacology;
therapeutic use;
RNA, Long Noncoding;
genetics
- From:
Chinese Journal of Lung Cancer
2018;21(2):121-128
- CountryChina
- Language:Chinese
-
Abstract:
Most non-small cell lung cancer patients with active epidermal growth factor receptor (EGFR) mutation will eventually acquire drug resistant to EGFR tyrosine kinase inhibitors, such as gefitinib, resulting in disease progression, which involves a variety of complex mechanisms. Up to now, the molecular mechanisms of long non-coding RNAs mediated EGFR-TKIs resistance remains poorly understood. This review aims to outline the current state of information on lncRNAs and progress on its role in EGFR-TKIs resistance in non-small cell lung cancer.
